Why Basilea Pharmaceutica stock is back in focus
Basilea Pharmaceutica (SWX:BSLN) is drawing fresh attention after reporting CHF 119 million in first half 2026 revenue and CHF 27.95 million in net income, along with higher full year guidance for both total revenue and operating profit.
See our latest analysis for Basilea Pharmaceutica.
The latest earnings and raised guidance have been met with a sharp shift in sentiment. Basilea Pharmaceutica’s share price return is 23.1% over 90 days and the 1 year total shareholder return is 38.1%, suggesting momentum has been building through 2026.
If strong recent results have you looking beyond Basilea Pharmaceutica, this could be a good moment to hunt for other healthcare opportunities using the 129 healthcare AI stocks
Basilea Pharmaceutica now appears to be a stronger, more profitable business, and the share price has moved quickly to reflect that. The key issue for you is whether the stock already embeds that progress or still offers value.
Price-to-earnings of 15.5x for Basilea Pharmaceutica: Is it justified?
Basilea Pharmaceutica is trading on a P/E of 15.5x, which sits below both the Swiss market average of 19.9x and the European biotech industry average of 22.9x. At the same time, the current share price of CHF65.60 is slightly above the estimate from the SWS DCF model, which points to a future cash flow value of CHF61.84.
The P/E ratio compares the current share price to annual earnings per share. For a commercial stage biotech like Basilea Pharmaceutica, it gives a snapshot of how much investors are paying for each unit of current earnings, rather than for distant pipeline potential. A 15.5x multiple suggests the market is not assigning an especially rich premium to those earnings compared with many peers.
Against other biotechs in Europe, Basilea Pharmaceutica trades at a discount to both the sector average P/E of 22.9x and a much higher peer group average of 92.1x. It also sits below an estimated fair P/E of 16.5x that the SWS fair ratio analysis suggests the market could gravitate toward if pricing aligned more closely with underlying drivers.
Explore the SWS fair ratio for Basilea Pharmaceutica
Result: Price-to-earnings of 15.5x
However, recent revenue contraction and only modest net income growth suggest that Basilea Pharmaceutica still faces execution risk, which could quickly challenge today’s more optimistic sentiment.
Find out about the key risks to this Basilea Pharmaceutica narrative.
Another view on Basilea Pharmaceutica’s valuation
The earlier P/E comparison paints Basilea Pharmaceutica as reasonably priced, but the SWS DCF model offers a cooler take. On this view, the stock at CHF65.60 sits above an estimated future cash flow value of CHF61.84, which points to a degree of overvaluation. How much weight do you give to cash flow assumptions versus earnings multiples?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Basilea Pharmaceutica for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 271 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
The mix of positive and cautious signals on Basilea Pharmaceutica can feel finely balanced, so it helps to review the data yourself and decide where you stand. To make that easier, take a closer look at the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Basilea Pharmaceutica?
If Basilea Pharmaceutica has sharpened your focus, do not stop there. The right screeners can quickly surface other stocks that match your style and risk comfort.
- Zero in on quality by reviewing companies highlighted in the solid balance sheet and fundamentals stocks screener (426 results) that pair healthier finances with more resilient fundamentals.
- Hunt for potential mispricings by scanning the 271 high quality undervalued stocks that filters for stronger businesses trading at what could be appealing valuations.
- Strengthen your income watchlist by checking the 434 dividend fortresses which focuses on higher yielding stocks that may offer steadier cash returns.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com